Identification

Name
Bicalutamide
Accession Number
DB01128  (APRD00042, DB06284)
Type
Small Molecule
Groups
Approved
Description

Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is a racemic mixture consisting of equal proportions of enantiomers (R)-bicalutamide and (S)-bicalutamide. Bicalutamide binds to the androgen receptor.

Structure
Thumb
Synonyms
  • Bicalutamida
  • Bicalutamide
  • Bicalutamidum
External IDs
ICI 176,334 / ICI-176334 / ICI176,334-1
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act BicalutamideTablet50 mgOralActavis Pharma Company2006-02-07Not applicableCanada
BicalutamideTablet50 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
BicalutamideTablet50 mgOralSorres Pharma Inc2009-06-222014-06-20Canada
Bicalutamide TabletsTablet50 mgOralFresenius KabiNot applicableNot applicableCanada
CasodexTablet50 mg/1OralAstraZeneca Pharnaceuticals LP2007-01-082007-01-08Us
CasodexTablet50 mg/1OralANI Pharmaceuticals, Inc.2018-06-26Not applicableUs
CasodexTablet50 mgOralAstra Zeneca1996-12-31Not applicableCanada
CasodexTablet50 mg/1OralAstraZeneca Pharmaceuticals LP1995-10-162019-09-30Us
CasodexTablet50 mg/1OralPhysicians Total Care, Inc.2002-06-04Not applicableUs
Sandoz BicalutamideTablet50 mgOralSandoz Canada Incorporated2006-02-08Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-bicalutamide Tablets USPTablet50 mgOralAccel Pharma IncNot applicableNot applicableCanada
Ach-bicalutamideTablet50 mgOralAccord Healthcare Limited2010-05-05Not applicableCanada
Ag-bicalutamideTablet50 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Apo-bicalutamideTablet50 mgOralApotex Corporation2007-11-05Not applicableCanada
Ava-bicalutamideTablet50 mgOralAvanstra Inc2011-11-232014-08-21Canada
BicalutamideTablet50 mg/1OralAccord Healthcare Inc.2009-07-06Not applicableUs
BicalutamideTablet, film coated50 mg/1OralSun Pharma Global Inc.2009-07-072017-07-31Us
BicalutamideTablet50 mg/1OralSandoz2009-07-062017-12-31Us
BicalutamideTablet, film coated50 mg/1OralNorth Star Rx Llc2009-08-28Not applicableUs16714 0571 01 nlmimage10 f0047873
BicalutamideTablet, film coated50 mg/1OralAmerincan Health Packaging2010-01-132013-08-31Us
Categories
UNII
A0Z3NAU9DP
CAS number
90357-06-5
Weight
Average: 430.373
Monoisotopic: 430.061040456
Chemical Formula
C18H14F4N2O4S
InChI Key
LKJPYSCBVHEWIU-UHFFFAOYSA-N
InChI
InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)
IUPAC Name
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorobenzenesulfonyl)-2-hydroxy-2-methylpropanamide
SMILES
CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F

Pharmacology

Indication

For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.

Associated Conditions
Pharmacodynamics

Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

Mechanism of action

Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.

TargetActionsOrganism
AAndrogen receptor
antagonist
Human
Absorption

Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown.

Volume of distribution
Not Available
Protein binding

96%

Metabolism

Bicalutamide undergoes stereo specific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation.

Route of elimination
Not Available
Half life

5.9 days

Clearance
  • Apparent oral cl=0.32 L/h [Normal Males]
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Bicalutamide.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Bicalutamide.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Bicalutamide.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Bicalutamide.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Bicalutamide.
5-androstenedioneThe metabolism of 5-androstenedione can be decreased when combined with Bicalutamide.
6-Deoxyerythronolide BThe metabolism of Bicalutamide can be decreased when combined with 6-Deoxyerythronolide B.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Bicalutamide.
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Bicalutamide.
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Bicalutamide.
Food Interactions
  • Take without regard to meals, at the same time everyday.

References

Synthesis Reference

Nnochiri Ekwuribe, "METHODS OF SYNTHESIZING ACYLANILIDES INCLUDING BICALUTAMIDE AND DERIVATIVES THEREOF." U.S. Patent US20020165406, issued November 07, 2002.

US20020165406
General References
Not Available
External Links
Human Metabolome Database
HMDB0015260
KEGG Drug
D00961
KEGG Compound
C08160
PubChem Compound
2375
PubChem Substance
46505386
ChemSpider
2284
BindingDB
18525
ChEBI
91617
ChEMBL
CHEMBL409
Therapeutic Targets Database
DAP000092
PharmGKB
PA164746255
IUPHAR
2863
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Bicalutamide
ATC Codes
L02BB03 — Bicalutamide
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (182 KB)
MSDS
Download (57.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Prostate Cancer / Stage IV Prostate Cancer1
0RecruitingTreatmentProstate Cancer1
1Active Not RecruitingTreatmentProstate Cancer2
1CompletedNot AvailableHealthy Volunteers2
1CompletedPreventionHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentProstate Cancer5
1TerminatedTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer1
1TerminatedTreatmentHealthy Volunteers2
1TerminatedTreatmentNon Castrate Metastatic Prostate Cancer1
1TerminatedTreatmentProstate Cancer1
1, 2Active Not RecruitingTreatmentProstate Cancer1
1, 2CompletedTreatmentProstate Cancer / Prostatic Neoplasms1
1, 2CompletedTreatmentProstatic Neoplasms1
1, 2RecruitingTreatmentAdenocarcinoma, Prostate / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer1
1, 2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
1, 2RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1, 2TerminatedTreatmentAndrogen-insensitive Prostate Cancer / Castrate-resistant Prostate Cancer (CRPC) / Hormone-Refractory Prostate Cancer / Metastatic Disease / Prostate Cancer / Prostatic Neoplasms1
1, 2TerminatedTreatmentProstate Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / Prostate Cancer / PSA Level Greater Than or Equal to 0.2 / PSA Progression / Recurrent Prostate Carcinoma1
2Active Not RecruitingTreatmentBone Metastases / Prostate Cancer / Prostate Neoplasms1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentErectile Dysfunction (ED) / Lower Urinary Tract Symptoms (LUTS) / Prostate Cancer1
2Active Not RecruitingTreatmentHormone-Resistant Prostate Cancer / Recurrent Prostate Carcinoma1
2Active Not RecruitingTreatmentProstate Cancer3
2Active Not RecruitingTreatmentRecurrent Prostate Carcinoma / Stage I Prostate Cancer / Stage I Prostate Cancer AJCC v7 / Stage IIA Prostate Cancer / Stage IIA Prostate Cancer AJCC v7 / Stage IIB Prostate Cancer / Stage IIB Prostate Cancer AJCC v7 / Stage III Prostate Cancer / Stage III Prostate Cancer AJCC v71
2CompletedTreatmentAdenocarcinoma of the Prostate / Prostate Cancer1
2CompletedTreatmentAdenocarcinoma of the Prostate / Stage IV Prostate Cancer1
2CompletedTreatmentAdenocarcinoma, Prostate / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2CompletedTreatmentAdenocarcinoma, Prostate / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer1
2CompletedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2CompletedTreatmentGynaecomastia / Prostate Cancer1
2CompletedTreatmentHormonal Cycling / Malignancies / Prostate1
2CompletedTreatmentProstate Cancer19
2CompletedTreatmentProstatic Neoplasms1
2CompletedTreatmentPuberty, Precocious1
2CompletedTreatmentRecurrent Prostate Carcinoma / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer1
2Not Yet RecruitingTreatmentBreast Neoplasm Female / Cancer, Breast / Carcinoma, Breast / Tumors, Breast1
2Not Yet RecruitingTreatmentNeoplasms, Breast1
2RecruitingTreatmentCancer, Breast2
2RecruitingTreatmentHigh-risk Prostate Cancer / Prostate Cancer1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentProstate Cancer5
2RecruitingTreatmentSalivary Gland Cancers1
2RecruitingTreatmentStage I Prostate Adenocarcinoma / Stage II Prostate Adenocarcinoma1
2TerminatedTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentProstatic Neoplasms1
2Unknown StatusTreatmentProstate Cancer1
2WithdrawnNot AvailableProstate Cancer1
2WithdrawnTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
2WithdrawnTreatmentProstate Cancer4
2, 3CompletedNot AvailableProstate Cancer1
2, 3RecruitingTreatmentStage I Prostate Adenocarcinoma / Stage II Prostate Adenocarcinoma / Stage III Prostate Adenocarcinoma1
3Active Not RecruitingTreatmentGastrointestinal Complications / Prostate Cancer / Sexual Dysfunctions / Urinary Complications1
3Active Not RecruitingTreatmentProstate Cancer9
3Active Not RecruitingTreatmentProstatic Neoplasms1
3CompletedHealth Services ResearchProstate Cancer1
3CompletedPreventionProstate Cancer1
3CompletedTreatmentNon-Metastatic Prostate Cancer3
3CompletedTreatmentProstate Cancer14
3RecruitingPreventionMetastatic Triple Negative Breast Cancer1
3RecruitingTreatmentCastration Levels of Testosterone / Metastatic Prostatic Adenocarcinoma / Stage IV Prostate Cancer AJCC v8 / Stage IVA Prostate Cancer AJCC v8 / Stage IVB Prostate Cancer AJCC v81
3RecruitingTreatmentHormone-dependent prostate cancer / Prostate Cancer1
3TerminatedTreatmentProstate Cancer5
3TerminatedTreatmentProstatic Neoplasms1
3Unknown StatusTreatmentProstate Cancer1
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentProstate Neoplasms1
4WithdrawnTreatmentMetastatic Hormone Refractory Prostate Cancer1
Not AvailableActive Not RecruitingNot AvailableProstate Cancer1
Not AvailableActive Not RecruitingTreatmentStage III Prostate Cancer1
Not AvailableCompletedPreventionOsteoporosis1
Not AvailableCompletedTreatmentProstatic Neoplasms1
Not AvailableNo Longer AvailableNot AvailableAdenocarcinoma of the Prostate1
Not AvailableNot Yet RecruitingTreatmentStage IV Prostate Cancer1
Not AvailableRecruitingNot AvailableProstate Cancer1
Not AvailableRecruitingTreatmentAdenocarcinoma of the Prostate1
Not AvailableRecruitingTreatmentProstate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Accord Healthcare
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • AstraZeneca Inc.
  • Cadila Healthcare Ltd.
  • DAVA Pharmaceuticals
  • Intas Pharmaceuticals Ltd.
  • Major Pharmaceuticals
  • Mylan
  • Sandoz
  • Schwarz Pharma Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Synthon Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Zydus Pharmaceuticals
Dosage forms
FormRouteStrength
Tablet, film coatedOral50 mg/1
TabletOral50 mg/1
TabletOral50 mg
Prices
Unit descriptionCostUnit
Casodex 50 mg tablet20.19USD tablet
Bicalutamide 50 mg tablet18.92USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)191-193 °CNot Available
water solubility5 mg/LNot Available
logP2.5Not Available
pKa12.0Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00928 mg/mLALOGPS
logP2.7ALOGPS
logP2.71ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)11.95ChemAxon
pKa (Strongest Basic)-4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area107.26 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity96.59 m3·mol-1ChemAxon
Polarizability36.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9471
Blood Brain Barrier+0.859
Caco-2 permeable-0.6085
P-glycoprotein substrateNon-substrate0.6741
P-glycoprotein inhibitor INon-inhibitor0.7171
P-glycoprotein inhibitor IINon-inhibitor0.9178
Renal organic cation transporterNon-inhibitor0.9572
CYP450 2C9 substrateNon-substrate0.6883
CYP450 2D6 substrateNon-substrate0.8087
CYP450 3A4 substrateNon-substrate0.5536
CYP450 1A2 substrateNon-inhibitor0.8513
CYP450 2C9 inhibitorNon-inhibitor0.6246
CYP450 2D6 inhibitorNon-inhibitor0.8683
CYP450 2C19 inhibitorInhibitor0.7976
CYP450 3A4 inhibitorInhibitor0.7879
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5662
Ames testNon AMES toxic0.7134
CarcinogenicityNon-carcinogens0.6067
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4383 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9959
hERG inhibition (predictor II)Non-inhibitor0.8759
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4r-0890000000-f2bd2727ffd1da47c463
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014r-2950100000-4088c17274bcf0f095d4
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014r-0980100000-89a3faa58e22068394b8

Taxonomy

Description
This compound belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Trifluoromethylbenzenes
Direct Parent
Trifluoromethylbenzenes
Alternative Parents
Anilides / Benzenesulfonyl compounds / Benzonitriles / N-arylamides / Fluorobenzenes / Aryl fluorides / Tertiary alcohols / Sulfones / Secondary carboxylic acid amides / Nitriles
show 6 more
Substituents
Trifluoromethylbenzene / Benzenesulfonyl group / Anilide / Benzonitrile / N-arylamide / Fluorobenzene / Halobenzene / Aryl fluoride / Aryl halide / Tertiary alcohol
show 22 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Details
1. Androgen receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Wang LG, Liu XM, Kreis W, Budman DR: Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol. 1998 May 1;55(9):1427-33. [PubMed:10076535]
  2. Chang HC, Miyamoto H, Marwah P, Lardy H, Yeh S, Huang KE, Chang C: Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11173-7. [PubMed:10500149]
  3. Laufer M, Sinibaldi VJ, Carducci MA, Eisenberger MA: Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer. Urology. 1999 Oct;54(4):745. [PubMed:10754148]
  4. Bouchal J, Kolar Z, Mad'arova J, Hlobilkova A, von Angerer E: The effects of natural ligands of hormone receptors and their antagonists on telomerase activity in the androgen sensitive prostatic cancer cell line LNCaP. Biochem Pharmacol. 2002 Mar 15;63(6):1177-81. [PubMed:11931851]
  5. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M: Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 2003 Jan 1;63(1):149-53. [PubMed:12517791]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Cockshott ID: Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78. [PubMed:15509184]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Cockshott ID: Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78. [PubMed:15509184]
  2. Bicalutamide [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Cockshott ID: Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78. [PubMed:15509184]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Cockshott ID: Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78. [PubMed:15509184]

Drug created on June 13, 2005 07:24 / Updated on November 20, 2018 00:51